Last week, Senator Bernie Sanders, I-Vermont, and Representative Elijah Cummings, D-Maryland, introduced legislation comprising 3 bills to curb the cost of prescription drugs.
Last week, Senator Bernie Sanders, I-Vermont, and Representative Elijah Cummings, D-Maryland, introduced legislation comprising 3 bills to curb the cost of prescription drugs.
The proposals introduced by Sanders and Cummings would allow the US to price prescription drugs at the median price from 5 countries: Canada, Britain, France, Germany, and Japan, where drug prices are usually significantly lower than in the United States. The legislation included the ability to open up generic competition to patent-protected US brand-name drugs that have been deemed “excessively priced.” A medication could achieve this designation if its price in the US is higher than the median price in the 5 aforementioned countries.
“Today I say to President Trump, if you are serious about lowering the cost of prescription drugs in this country, support our legislation and get your Republican colleagues on board,” said Sanders at a Capitol Hill press conference.
The proposal echoes a similar proposition made my HHS Secretary Alex Azar in October 2018, the International Pricing Index, whereby Medicare would more closely align its payment amount for select Part B drugs with prices paid in other nations.
Additionally, the legislation newly introduced by Sanders and Cummings would also allow HHS to negotiate prices in Medicare Part D, as well as allow consumers import lower-priced medications from Canada.
Lobbying group the Pharmaceutical Research and Manufacturers of America (PhRMA) came out against the proposal, stating that it “would wreak havoc on the US healthcare system. They would interfere with patient access to medicine, while also undermining the US intellectual property system, replicating the flawed policies of foreign governments and circumventing the [FDA]’s robust safety standards.”
The administration did not immediately comment on the proposed legislation.
Addressing ever-increasing drug prices in the United States has become a main focus of US politics since early 2018 when the Trump administration began introducing proposals to bring down drug costs. The introduced policy changes have received criticism from both sides of the aisle, with some stakeholders in the pharmaceutical industry alleging that the changes go further than legally allowed, while many Democrats have said the proposals don’t go far enough.
While several pharmaceutical companies temporarily froze prices on certain drugs last year, since the start of 2019 drug manufacturers have raised prices on more than 250 products, though most increases were under 10%.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.